🧪Decoding GLP-1 Scams: A Consumer’s Guide
This post is to make alerts consumers to various deceptive practices surrounding GLP-1 medications, which are often used for weight loss and diabetes management. It highlights risks associated with unregulated compounded injections from online clinics, stressing that only FDA-approved drugs from licensed pharmacies are proven safe. The guide also exposes false claims made by oral supplements, sprays, […]
GLP-1 is changing taste: How can food makers reignite flavour?
GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and focusing on nutrient-dense, portion-controlled products.
Food Noise: Unwanted and Persistent Thoughts About Food
Food noise is the constant, unwanted mental concerns about food. It’s not hunger, and it may ease with GLP-1 medications, psychological therapy, rather than willpower.
Obesity Reversed in Genome Edited Mice that Produce Their Own GLP-1
Weight-loss and diabetes drugs like GLP-1 receptor agonists have reshaped the treatment landscape, but they come with a catch: frequent injections to maintain their effects. Now, researchers in Japan have taken a striking step toward rewriting this paradigm by turning the liver into a long-term GLP-1 producer. In a study titled “Targeted In Vivo Gene […]
Tirzepatide reduces food intake and appetite, and affects brain functioning, more than placebo and liraglutide
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and liraglutide. These results were recently published in Nature Medicine in the study titled “Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized […]
Can Orforglipron ACHIEVE the Unattainable?
The ACHIEVE-1 trial has positioned orforglipron as an efficacious oral GLP-1 RA that could scale globally for the treatment of early type 2 diabetes and weight management. Medscape Diabetes & Endocrinology
Novo Nordisk Submits Higher Wegovy Dose for EMA Approval
Denmark’s Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three… Reuters Health Information
New study identifies factors linked to successful weight loss using GLP-1RAs
A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people’s weight loss after taking prescription drugs called glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide (sold under the brand names Ozempic and Wegovy).
Danone-owned Kate Farms shakes up high-protein space with GLP-1 drinks
IFT First: New tech and innovations to look out for at the food science expo
IFT First, the global food science and innovation expo, showcases cutting-edge advancements in food and beverage technology: including GLP-1 innovations, functional ingredients, plant-based protein and more.